Array Biopharma and Asahi Kasei Pharma Announce Collaboration for Pain and Inflammation Program
Friday, April 01, 2016
Array Biopharma Inc Co, Asahi Kasei Pharma corporation announce development and commercialization collaboration for novel pain and inflammation program.
Array to receive $12 million in up-front payment and up to $64 million in additional development and commercialization milestones.
Array retains full commercialization rights for all compounds in all indications in territories outside of Asia.
Within Asia retains full rights to cancer indications for all compounds excluding those being developed by Asahi Kasei Pharma.
Asahi will have exclusive rights to develop and commercialize products in Japan , Korea, Taiwan and China for pain, inflammation.
Source : reuters.com
